ArticleAntibiotics (Basel, Switzerland)2020
Novel Antimicrobial Peptide from Temporin L in The Treatment of
Article in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Boosting AMPs' Power: From Structural Engineering to Nanotechnology-Based Delivery.Molecules (Basel, Switzerland) · 2025Review
- Methicillin-resistant Staphylococcus pseudintermedius: epidemiological changes, antibiotic resistance, and alternative therapeutic strategies.Veterinary research communications · 2024Review
- Antimicrobial Strategies Proposed for the Treatment ofVeterinary sciences · 2024Review
- Unveiling the mechanism of action of acylated temporin L analogues against multidrug-resistantJournal of enzyme inhibition and medicinal chemistry · 2023Article
- Designing New Hybrid Antibiotics: Proline-Rich Antimicrobial Peptides Conjugated to the Aminoglycoside Tobramycin.Bioconjugate chemistry · 2023Article
- Glycosylation and Lipidation Strategies: Approaches for Improving Antimicrobial Peptide Efficacy.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Myxinidin-Derived Peptide against Biofilms Caused by Cystic Fibrosis Emerging Pathogens.International journal of molecular sciences · 2023Article
- Synthetic Amphipathic β-Sheet Temporin-Derived Peptide with Dual Antibacterial and Anti-Inflammatory Activities.Antibiotics (Basel, Switzerland) · 2022Article
- Antimicrobial Activity of a Lipidated Temporin L Analogue against Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2021Article
- Synergism of a Novel 1,2,4-oxadiazole-containing Derivative with Oxacillin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
- First-in-Class Cyclic Temporin L Analogue: Design, Synthesis, and Antimicrobial Assessment.Journal of medicinal chemistry · 2021Article
- Carriage of Multidrug Resistance Staphylococci in Shelter Dogs in Timisoara, Romania.Antibiotics (Basel, Switzerland) · 2021Article
- Synergistic Effect of Abietic Acid with Oxacillin against Methicillin-ResistantAntibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interkingdom polymicrobial diseases are caused by different microorganisms that colonize the same niche, as in the case of yeast-bacteria coinfections. The latter are difficult to treat due the absence of any common therapeutic target for their elimination, both in animals and humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.